Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.8% year on year to $194.3 million. On the other hand, the company’s full-year revenue guidance of $818 million at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $0.48 per share was 24.9% above analysts’ consensus estimates.

Is now the time to buy Repligen? Find out by accessing our full research report, it’s free.

Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We delivered a very strong start to the year, achieving 11% organic revenue growth and 160 basis points of adjusted operating margin expansion, exceeding expectations as our team executed well across the business. Combined with recent order trends, these results reinforce our confidence in our full-year revenue outlook.”

Company Overview

With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ: RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Repligen’s sales grew at a solid 12% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Repligen’s annualized revenue growth of 10.9% over the last two years is below its five-year trend, but we still think the results were respectable.

We can dig further into the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Repligen’s organic revenue averaged 9.9% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results.

This quarter, Repligen reported year-on-year revenue growth of 14.8%, and its $194.3 million of revenue exceeded Wall Street’s estimates by 1.3%.

Looking ahead, sell-side analysts expect revenue to grow 12.2% over the next 12 months, similar to its two-year rate. This projection is commendable and implies its newer products and services will fuel better top-line performance.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

Repligen has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 19.9%.

Analyzing the trend in its profitability, Repligen’s adjusted operating margin decreased by 18.1 percentage points over the last five years, but it rose by 1.6 percentage points on a two-year basis. Still, shareholders will want to see Repligen become more profitable in the future.

This quarter, Repligen generated an adjusted operating margin profit margin of 15.4%, up 1.6 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Sadly for Repligen, its EPS declined by 2.3% annually over the last five years while its revenue grew by 12%. This tells us the company became less profitable on a per-share basis as it expanded.

Diving into the nuances of Repligen’s earnings can give us a better understanding of its performance. As we mentioned earlier, Repligen’s adjusted operating margin expanded this quarter but declined by 18.1 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, Repligen reported adjusted EPS of $0.48, up from $0.39 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Repligen’s full-year EPS of $1.80 to grow 17.2%.

Key Takeaways from Repligen’s Q1 Results

It was good to see Repligen beat analysts’ EPS expectations this quarter. We were also happy its full-year EPS guidance outperformed Wall Street’s estimates. On the other hand, its full-year revenue guidance slightly missed. Overall, this print had some key positives. The stock traded up 3.1% to $121.84 immediately after reporting.

Repligen may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).